What is NDC 51662-1505?

51662-1505 is the product NDC for Lidocaine Hci And Epinephrine, Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .01 mg/mL injection, solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.

What is the active ingredient?

Lidocaine hydrochloride anhydrous, Epinephrine bitartrate.

HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lidocaine Hci And Epinephrine?

2 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lidocaine Hci And Epinephrine NDC 51662-1505

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1505Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1505Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1505-1	5166215050151662150501	50 mL in 1 VIAL, MULTI-DOSE (51662-1505-1)Marketed from Mar 11, 2020
51662-1505-3	5166215050351662150503	25 POUCH in 1 CASE (51662-1505-3) / 1 VIAL, MULTI-DOSE in 1 POUCH (51662-1505-2) / 50 mL in 1 VIAL, MULTI-DOSEMarketed from Mar 17, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lidocaine Hci And Epinephrine
Generic name (nonproprietary): lidocaine hci and epinephrine
Active ingredients: Lidocaine hydrochloride anhydrous — 20 mg/mLEpinephrine bitartrate — .01 mg/mL
Dosage form: Injection, Solution
Route: Infiltration, Perineural
Labeler: HF Acquisition Co LLC, DBA HealthFirstNDC labeler code 51662
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 006488
Marketing start: Mar 11, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)Adrenergic beta-Agonists (Mechanism)Amides (Chemical structure)Catecholamines (Chemical structure)Local Anesthesia (Physiologic effect)
Identifiers: Product ID 51662-1505_12048ce4-ce14-44c3-e063-6394a90ace48SPL ID 12048ce4-ce14-44c3-e063-6394a90ace48SPL set ID a0997348-6274-060a-e053-2a95a90abea7RxCUI 1010759UNII EC2CNF7XFP, 30Q7KI53AKUPC 0363323483012
Pharmacologic class: Amide Local Anesthetic; Antiarrhythmic; Catecholamine; alpha-Adrenergic Agonist; beta-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N451662150501 followed by a unit qualifier and the quantity

Package 51662-1505-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 22, 2024.

Indications (excerpt from the label)

INDICATIONS & USAGE Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51662-1505

What is NDC 51662-1505?: 51662-1505 is the product NDC for Lidocaine Hci And Epinephrine, Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .01 mg/mL injection, solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lidocaine Hci And Epinephrine.
What is the active ingredient?: Lidocaine hydrochloride anhydrous, Epinephrine bitartrate.
Who is the labeler?: HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lidocaine Hci And Epinephrine?: 2 other product NDCs are listed under this name. See all Lidocaine Hci And Epinephrine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Lidocaine Hci And Epinephrine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Lidocaine Hci And Epinephrine	Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .01 mg/mL	Injection, SolutionInfiltration, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1506	51662-1506-0151662-1506-0251662-1506-03
Lidocaine Hci And Epinephrine	Lidocaine hydrochloride 10 mg/mL; Epinephrine 10 ug/mL	Injection, SolutionInfiltration, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1395	51662-1395-0151662-1395-03

Other NDCs under NDA 006488

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 006488
Product	Strength	Form · route	Labeler	Product NDC
Xylocainelidocaine hydrochloride and epinephrine	Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .005 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Henry Schein, Inc.	0404-9972
XYLOCAINE- MPF (LIDOCAINE HCl )lidocaine hcl	Lidocaine hydrochloride anhydrous 20 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1604
Xylocaine	Epinephrine bitartrate .01 mg/mL; Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionInfiltration, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1622
Xylocainelidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 10 mg/mL; Epinephrine bitartrate .01 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-482
Xylocainelidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 5 mg/mL; Epinephrine bitartrate .005 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-481
Xylocainelidocaine hydrochloride	Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-485
Xylocainelidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 10 mg/mL; Epinephrine bitartrate .01 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-482
Xylocainelidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .01 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-483
Xylocainelidocaine hydrochloride	Lidocaine hydrochloride anhydrous 5 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-484
Xylocainelidocaine hydrochloride	Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-485
Xylocainelidocaine hydrochloride	Lidocaine hydrochloride anhydrous 20 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-486
Xylocainelidocaine hydrochloride	Lidocaine hydrochloride anhydrous 20 mg/mL	Injection, SolutionInfiltration, Perineural	Fresenius Kabi USA, LLC	63323-486
Xylocaine MPFlidocaine hydrochloride	Lidocaine hydrochloride anhydrous 5 mg/mL	Injection, SolutionInfiltration	Fresenius Kabi USA, LLC	63323-491
Xylocaine MPFlidocaine hydrochloride	Lidocaine hydrochloride anhydrous 10 mg/mL; Epinephrine bitartrate .005 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Fresenius Kabi USA, LLC	63323-487
Xylocaine MPFlidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 15 mg/mL; Epinephrine bitartrate .005 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Fresenius Kabi USA, LLC	63323-488
Xylocaine MPFlidocaine hydrochloride,epinephrine bitartrate	Lidocaine hydrochloride anhydrous 20 mg/mL; Epinephrine bitartrate .005 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Fresenius Kabi USA, LLC	63323-489
Xylocaine MPFlidocaine hydrochloride	Lidocaine hydrochloride anhydrous 15 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Fresenius Kabi USA, LLC	63323-493
Xylocaine Mpf	Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1644
Xylocaine MPFlidocaine hydrochloride	Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionEpidural, Infiltration, Intracaudal, Perineural	Fresenius Kabi USA, LLC	63323-492
Xylocaine	Lidocaine hydrochloride anhydrous 10 mg/mL	Injection, SolutionInfiltration, Perineural	HF Acquisition Co LLC, DBA HealthFirst	51662-1645

Showing 20 of 40.